The National Coalition on Health Care applauds the bipartisan, bicameral “surprise billing” legislation released on Friday, December 12. The National Coalition on Health Care has long called for this action. John Rother, President of the Coalition, praised the bipartisan legislation as a necessary move to protect patients, especially during the COVID-19 pandemic, and a step […]
As part of its mission to bring together stakeholders to achieve an affordable, high-value health system, NCHC advocates for constructive policy change. While some members of NCHC do not, or cannot, take positions either on specific legislation, strategies, or on any policies outside their respective mission areas, all that can, do endorse broad policy positions in support of comprehensive health system change. Here is the policy correspondence sent from the National Coalition on Health Care.
Here, you will find all of NCHC's policy correspondence from 2017-present. Please see here for all 2016 and previous policy correspondence.
Washington, D.C. – The National Coalition on Health Care (NCHC) released a statement opposing the the Administration’s approach to address drug pricing through the two rules released Friday, November 20. The rules – removing the current rebate safe harbor in Medicare Part D and establishing a “Most Favored Nation” Model in Part B – rightly […]
The National Coalition on Health Care (NCHC) opposes the Administration’s approach to address drug pricing through the “Most-Favored-Nation” (MFN) executive order released yesterday. The executive order rightly recognizes the urgency of addressing exorbitant drug prices, for the sake of the Medicare program and for its beneficiaries, but we encourage the White House to apply this […]
The National Coalition on Health Care (NCHC) strongly opposes theAdministration’s approach to address drug pricing through the executive orders released today. The executive orders rightly recognize the urgency of addressing drug prices, but we encourage the White House to pursue more comprehensive options proposed by the House and Senate. “Specialty and many branded drugs have […]
On Monday, June 29, Gilead announced the pricing of remdesivir, an anti-viral drug that treats COVID-19. The Coalition supports protecting consumers from unaffordable drug costs. The pricing decision will exacerbate the health care affordability crisis already plaguing the country’s response to COVID-19. Fundamentally, the United States needs to develop a fair drug pricing system that […]